MRSA Surveillance Across 269 and 217 U.S. Athletic Programs

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

Reader question: What did this specific study measure, in whom, at what timepoint—and what would go beyond its evidence?

Study snapshot

Study element	Reported detail
Population	Athletic trainers from 269 high-school and collegiate programs in 2015–2016 and 217 programs reporting bimonthly in 2016–2017.
Design	Two-season questionnaire surveillance of physician-confirmed community-associated MRSA infection and management practices.
Comparator	Incidence was compared across years and sports, especially wrestling and football.
Timepoint	Academic years 2015–2016 and 2016–2017.
Key result	Estimated incidence was 26.8 per 10,000 athletes (95% CI 24–30) in 2015–2016 and 20.3 (18–23) in 2016–2017. Wrestling incidence was 248.3 (204–302) then 100.0 (66–151); football incidence was 71.0 (60–85) then 81.8 (68–99) per 10,000.
Funding/conflict context	The PubMed abstract does not state funding or conflicts. No moisturizer or cosmetic intervention was evaluated.

What was actually measured?

Estimated incidence was 26.8 per 10,000 athletes (95% CI 24–30) in 2015–2016 and 20.3 (18–23) in 2016–2017. Wrestling incidence was 248.3 (204–302) then 100.0 (66–151); football incidence was 71.0 (60–85) then 81.8 (68–99) per 10,000.

Physician confirmation and confidence intervals improve surveillance quality, but changing program participation can influence between-year differences.

The denominator defines the scope. A workplace outbreak, clinic series, questionnaire, case report and long-term cohort answer different questions. Their percentages and odds ratios cannot be silently transferred to another population.

What the result does not prove

Trainer-reported program data, different samples by year, incomplete capture outside athletics and observational management data prevent efficacy conclusions.

Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors’ conclusions, this interpretation or any product.

Exposure detail matters more than the job label

People with the same title may handle different materials for different durations. Useful documentation identifies the exact product or process, route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.

A symptom survey can identify a pattern, clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.

Questions worth recording

Which task, product, glove, tool, chemical, plant, dust or surface came before symptoms?
Where did the change begin, and did it improve away from work or after a process or PPE change?
How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
Were labels, ingredients and safety-data sheets reviewed with occupational health?
Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?

Prevention comes before cosmetic care

Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.

Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.

Primary research and guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.

← Back to Doctor's Notes